Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives
Authors
Keywords
-
Journal
Clinical & Translational Oncology
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-01
DOI
10.1007/s12094-018-1975-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials
- (2018) James J Harding Future Oncology
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients
- (2018) Boyang Chang et al. LIVER INTERNATIONAL
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy
- (2018) Hyun Ju Kim et al. RADIOTHERAPY AND ONCOLOGY
- CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage
- (2018) Kuan Hu et al. Translational Oncology
- Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
- (2018) Merly Contratto et al. World Journal of Gastrointestinal Oncology
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial experience of combination nivolumab and local-regional treatment in patients with advanced hepatocellular carcinoma (HCC).
- (2018) Ping Gu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- (2017) P. S. Chowdhury et al. JOURNAL OF INTERNAL MEDICINE
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
- (2017) Masatoshi Kudo ONCOLOGY
- Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
- (2017) Brian D. Friend et al. PEDIATRIC BLOOD & CANCER
- Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
- (2017) Hae Il Jung et al. Cancer Research and Treatment
- Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments
- (2017) Ali Raufi et al. Cancer Management and Research
- Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer
- (2017) Zachary J. Brown et al. Journal for ImmunoTherapy of Cancer
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
- (2016) Alexander Semaan et al. VIRCHOWS ARCHIV
- Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
- (2016) Xian-Shu Gao et al. OncoTargets and Therapy
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma
- (2016) Chang-Long Chen et al. OncoImmunology
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- The yin and yang of evasion and immune activation in HCC
- (2015) Oxana V. Makarova-Rusher et al. JOURNAL OF HEPATOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions
- (2014) Tai Hato et al. HEPATOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy
- (2014) Yuichiroh Umemoto et al. JOURNAL OF GASTROENTEROLOGY
- Dynamic Expression Patterns of Differential Proteins during Early Invasion of Hepatocellular Carcinoma
- (2014) Rong-Xin Chen et al. PLoS One
- Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma
- (2014) Yun Wang et al. TUMOR BIOLOGY
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular Carcinoma
- (2011) Zhen Zeng et al. PLoS One
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Chronically inflamed livers up-regulate expression of inhibitory B7 family members
- (2009) Rachel Kassel et al. HEPATOLOGY
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model
- (2009) Zubing Chen et al. INTERNATIONAL JOURNAL OF HYPERTHERMIA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Treatment and prognosis of hepatocellular carcinoma: A population based study in France
- (2008) Frédéric Borie et al. JOURNAL OF SURGICAL ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More